Results 151 to 160 of about 6,487 (164)

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Lancet, The, 2021
Andrew Blauvelt, D Thaçi, Chia Yu Chu
exaly  

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2021
Kristian Reich, Marjolein de Bruin-Weller, Thomas Bieber   +2 more
exaly  

Inflammatory Breast Cancer: The Disease, the Biology, the Treatment

Ca-A Cancer Journal for Clinicians, 2010
Luc M Bidaut, Wendy A Woodward, Anthony Lucci   +2 more
exaly  

Atopic dermatitis

Lancet, The, 2020
Sinead M Langan, Alan D Irvine, Stephan Weidinger   +2 more
exaly  

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Lancet, The, 2022
exaly  

Atopic dermatitis

Nature Reviews Disease Primers, 2018
Stephan Weidinger, Lisa A Beck, Thomas Bieber   +2 more
exaly  

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2022
exaly  

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Lancet, The, 2017
Andrew Blauvelt, Marjolein de Bruin-Weller, Melinda Gooderham   +2 more
exaly  

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

Lancet, The, 2016
D Thaçi, Lisa A Beck, Thomas Bieber
exaly  

Atopic dermatitis

Lancet, The, 2016
Stephan Weidinger, Natalijia Novak
exaly